Tema Oncology ETF (CANC)
NASDAQ: CANC
· Real-Time Price · USD
26.69
-0.01 (-0.06%)
At close: Aug 18, 2025, 3:58 PM
26.69
0.00%
After-hours: Aug 18, 2025, 04:10 PM EDT
-0.06% (1D)
| Bid | 26 |
| Market Cap | 67.96M |
| AUM | 69.2M |
| NAV | 26.31 |
| EPS (ttm) | 1.06 |
| PE Ratio (ttm) | 25.13 |
| Shares Out | 2.55M |
| Inception Date | Aug 14, 2023 |
| Ask | 34.31 |
| Volume | 8.65K |
| Open | 26.87 |
| Previous Close | 26.70 |
| Day's Range | 26.69 - 26.94 |
| 52-Week Range | 20.10 - 30.11 |
| Holdings | 53 |
| Expense Ratio | 0.75% |
About CANC
The actively managed Tema Oncology ETF seeks to provide long-term growth by investing in companies operating in the oncology industry. Cancer is the second deadliest killer but is on the brink of a revolution in therapeutics and diagnosis. Genetic sequencing and other forces are leading to a productivity surge, with oncology leading the way in new drug approvals.
Asset Class Equity
Ticker Symbol CANC
Inception Date Aug 14, 2023
Provider Other
Website Fund Home Page
Exchange NASDAQ
Top 10 Holdings 42.70% of assets
| Name | Symbol | Weight |
|---|---|---|
| Bridgebio Pharma, In... | BBIO | 5.19% |
| Roche Holding Ag | RHHBY | 4.86% |
| Revolution Medicines... | RVMD | 4.75% |
| Merus N.v. | MRUS | 4.47% |
| Astrazeneca Plc | AZN.L | 4.23% |
| Summit Therapeutics ... | SMMT | 4.18% |
| Novartis Ag | NOVN.SW | 4.18% |
| Genmab A/s | GMAB | 3.81% |
| Eli Lilly And Compan... | LLY | 3.60% |
| Exelixis, Inc. | EXEL | 3.43% |
Dividends Dividend Yield 2.78%
| Ex-Dividend | Amount | Payment Date |
|---|---|---|
| Dec 11, 2024 | $0.7283 | Dec 12, 2024 |
| Dec 13, 2023 | $0.1491 | Dec 15, 2023 |
